372 related articles for article (PubMed ID: 25023617)
1. Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly.
Chow MJ; Licona C; Yuan Qiang Wong D; Pastorin G; Gaiddon C; Ang WH
J Med Chem; 2014 Jul; 57(14):6043-59. PubMed ID: 25023617
[TBL] [Abstract][Full Text] [Related]
2. Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes.
Chow MJ; Babak MV; Wong DY; Pastorin G; Gaiddon C; Ang WH
Mol Pharm; 2016 Jul; 13(7):2543-54. PubMed ID: 27174050
[TBL] [Abstract][Full Text] [Related]
3. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
4. Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
Ji L; Zheng W; Lin Y; Wang X; Lü S; Hao X; Luo Q; Li X; Yang L; Wang F
Eur J Med Chem; 2014 Apr; 77():110-20. PubMed ID: 24631730
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium(II) carbonyl complexes containing S-methylisothiosemicarbazone based tetradentate ligand: synthesis, characterization and biological applications.
Selvamurugan S; Ramachandran R; Viswanathamurthi P
Biometals; 2013 Oct; 26(5):741-53. PubMed ID: 23780567
[TBL] [Abstract][Full Text] [Related]
6. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
7. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of new salicylaldehyde-2-picolinylhydrazone Schiff base compounds of Ru(II), Rh(III) and Ir(III) as in vitro antitumor, antibacterial and fluorescence imaging agents.
Palepu NR; Nongbri SL; Premkumar JR; Verma AK; Bhattacharjee K; Joshi SR; Forbes S; Mozharivskyj Y; Thounaojam R; Aguan K; Kollipara MR
J Biol Inorg Chem; 2015 Jun; 20(4):619-38. PubMed ID: 25712889
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.
Chen Y; Qin MY; Wu JH; Wang L; Chao H; Ji LN; Xu AL
Eur J Med Chem; 2013; 70():120-9. PubMed ID: 24141202
[TBL] [Abstract][Full Text] [Related]
10. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel anticancer ruthenium-arene pyridinylmethylene scaffolds via three-component reaction.
Jadhav GR; Sinha S; Chhabra M; Paira P
Bioorg Med Chem Lett; 2016 Jun; 26(11):2695-700. PubMed ID: 27090558
[TBL] [Abstract][Full Text] [Related]
12. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.
Hayward RL; Schornagel QC; Tente R; Macpherson JS; Aird RE; Guichard S; Habtemariam A; Sadler P; Jodrell DI
Cancer Chemother Pharmacol; 2005 Jun; 55(6):577-83. PubMed ID: 15726367
[TBL] [Abstract][Full Text] [Related]
14. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular "light switch" complexes.
Shobha Devi C; Anil Kumar D; Singh SS; Gabra N; Deepika N; Kumar YP; Satyanarayana S
Eur J Med Chem; 2013 Jun; 64():410-21. PubMed ID: 23665797
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents.
Lucas SJ; Lord RM; Wilson RL; Phillips RM; Sridharan V; McGowan PC
Dalton Trans; 2012 Dec; 41(45):13800-2. PubMed ID: 23015068
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
18. Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.
Ludwig G; Mijatović S; Ranđelović I; Bulatović M; Miljković D; Maksimović-Ivanić D; Korb M; Lang H; Steinborn D; Kaluđerović GN
Eur J Med Chem; 2013 Nov; 69():216-22. PubMed ID: 24042044
[TBL] [Abstract][Full Text] [Related]
19. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
[TBL] [Abstract][Full Text] [Related]
20. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
